menu
    • menu
    [{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF T1D","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ JDRF T1D","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ JDRF T1D"},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alize Pharma 3 Announces Rebranding to Amolyt Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alize\u0301 Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GL0034","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProLynx announces SBIR Arant Award to Develop Long-Ating Parathyroid Hormone for Hypo-Parathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"PTH(1-34)","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ National Institute of Health"},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"University of Pittsburgh \/ National Institutes of Health"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$34.6 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PreveCeutical Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Not Applicable"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Raises \u20ac28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Sofinnova Partners"},{"orgOrder":0,"company":"W. L. Gore & Associates","sponsor":"ViaCyte Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Stem cell-derived pancreatic islet cell progenitors","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"W. L. Gore & Associates","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"W. L. Gore & Associates \/ ViaCyte","highestDevelopmentStatusID":"4","companyTruncated":"W. L. Gore & Associates \/ ViaCyte"},{"orgOrder":0,"company":"University of Geneva","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology Expanding the Use of TNX-1900","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Geneva","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Geneva \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"University of Geneva \/ Tonix Pharmaceuticals"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of \u20ac35m","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Roche Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Roche Venture Fund"},{"orgOrder":0,"company":"Seraxis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seraxis Announced Closing of $40M Series C Financing Round","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"SR-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Seraxis","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Seraxis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Seraxis \/ Eli Lilly"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Ohio State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX to Collaborate with The Ohio State University to Generate Animal Data for AgeX\u2019s BAT Cell Therapy Candidate for Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"AgeX-BAT1","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Ohio State University"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nexturn Bio Inc. Decided to Invest in the Development of A New Drug Pipeline for Diabetes Treatment Using miRNA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"miRNA based therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Nexturn Bio"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Astressin B","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sentia Medical Science","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Nexturn Bio Inc. Acquired a 50% Stake in Ros Vivo Therapeutics, Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"miRNA Based Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Nexturn Bio"},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Development of BioVie\u2019s NE3107 Asset Featured by the American Diabetes Association","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"17\u03b1-ethynyl-androst-5-ene-3,7,17-triol","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioVie \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MKP10241","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Protomer Technologies","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lilly Announces Acquisition of Protomer Technologies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Glucose Responsive Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Protomer Technologies","amount2":1,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Protomer Technologies \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Protomer Technologies \/ Eli Lilly"},{"orgOrder":0,"company":"GentiBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$157.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"Engineered Regulatory T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"GentiBio","amount2":0.16,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"GentiBio \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"GentiBio \/ Matrix Capital Management"},{"orgOrder":0,"company":"Neurodon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curative Potential for Diabetes, Alzheimer\u2019s and Parkinson\u2019s Seen in Research Data Highlighted at Neurodon\u2019s 2nd Annual Scientific Advisory Board Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NDC-0009","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Neurodon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurodon \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurodon \/ Not Applicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RTX-T1D","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Nano Precision Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Nano Precision Medical","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Medical \/ Nano Precision Medical"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"PerkinElmer","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PerkinElmer\u2019s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirion Biotech","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ PerkinElmer","highestDevelopmentStatusID":"4","companyTruncated":"Sirion Biotech \/ PerkinElmer"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RosVivo Therapeutics, Inc. Signed a Material Transfer Agreement (MTA) for First-In-Class Diabetes Treatment With Eli Lilly and Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"RSVI-301","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RosVivo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"University of Sheffield","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Delayed Clearance Parathyroid Hormone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aeterna Zentaris \/ University of Sheffield","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Zentaris \/ University of Sheffield"},{"orgOrder":0,"company":"eGenesis","sponsor":"University of Miami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"HuCo Islet Cells","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"eGenesis \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ University of Miami"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"National Institute of Diabetes and Digestive Kidney Disease","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703\u2019s Potential to Reverse Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease","highestDevelopmentStatusID":"4","companyTruncated":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ\u00ae TAC Platform\u2019s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"RBC-derived Engineered Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"T1D Antigen-specific Nanoparticle","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ JDRF"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Medical College of Wisconsin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate's Adenosine Compounds as Potential Treatments for Diabetes and NASH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Medical College of Wisconsin","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Medical College of Wisconsin"},{"orgOrder":0,"company":"Civica Rx","sponsor":"GeneSys Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Civica Rx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Civica Rx \/ GeneSys Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Civica Rx \/ GeneSys Biologics"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RTX-T1D","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Sernova Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Sernova Announce Exclusive Strategic Partnership For iPSC-based Beta Cell Replacement Therapy to Advance a 'functional Cure' for Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"iPSC-based Beta Cell Replacement Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evotec \/ Sernova Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Sernova Corp."},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Second Sight Medical Products","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$55.0 million","newsHeadline":"Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Second Sight Medical Products","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Medical \/ Second Sight Medical Products"},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. to Present at the Virtual Investor Pioneering Regenerative Medicine Without Immunosuppression Roundtable Event","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"iTOL-101","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition Corp.","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"Conduit Pharmaceuticals to Become a Publicly Traded Company via Merger with Murphy Canyon Acquisition Corp.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"AZD5904","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition Corp."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"TFC-039","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pancreatic GLP-1 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Not Applicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"IFF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"M008","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MRM Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ IFF","highestDevelopmentStatusID":"4","companyTruncated":"MRM Health \/ IFF"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"Genprex","sponsor":"University of Pittsburgh","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ University of Pittsburgh"},{"orgOrder":0,"company":"Genprex","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ University of Pittsburgh"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"French Biotech Company AdipoPharma Secures Series A Funding for Groundbreaking Diabetes Drug","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"PATAS","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"XOMA","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"AZP-40XX","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Amolyt Pharma","highestDevelopmentStatusID":"4","companyTruncated":"XOMA \/ Amolyt Pharma"},{"orgOrder":0,"company":"iTolerance","sponsor":"Diabetes Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. Enters into Master Services Agreement with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine to Advance iTOL-100 Platform Technology for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Allogenic Pancreatic Islets","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Diabetes Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Diabetes Research Institute"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem\u00ae Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Brown Adipose-derived Stem Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. Completes Pre-IND Meeting with U.S. FDA for Development Program as a Potential Cure for Type 1 Diabetes Without the Need for Life-long Immunosuppression","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Stem Cell-derived Pancreatic Islets","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Not Applicable"},{"orgOrder":0,"company":"Lygenesis","sponsor":"Imagine Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lygenesis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lygenesis \/ Imagine Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lygenesis \/ Imagine Pharma"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. Announces Issuance of U.S. Patent Covering Proprietary Regenerative SA-FasL Microgel Technology, iTOL-100","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"iTOL-100","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Not Applicable"},{"orgOrder":0,"company":"Sernova","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sernova","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sernova \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Sernova \/ AstraZeneca"},{"orgOrder":0,"company":"DiogenX","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiogenX Raises \u20ac27.5M Series A Financing To Advance its First-in-class Regenerative Treatment For Type 1 Diabetes into Clinical Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"DiogenX","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"DiogenX \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"DiogenX \/ Boehringer Ingelheim Venture Fund"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"iTolerance","sponsor":"BIRD Foundation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. Receive US $1.0 Million Grant from the BIRD Foundation","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ BIRD Foundation","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ BIRD Foundation"},{"orgOrder":0,"company":"Septerna","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Septerna","amount2":0.14999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Septerna \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Septerna \/ RA Capital Management"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"Remedium Bio","sponsor":"National Science Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Remedium Awarded National Science Foundation (NSF) Innovation Grant","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"RMD1202","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Remedium Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Remedium Bio \/ National Science Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Remedium Bio \/ National Science Foundation"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"iTolerance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for the Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"iTOL-102","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ iTolerance","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ iTolerance"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$344.2 million","upfrontCash":"$344.2 million","newsHeadline":"Lilly Completes Acquisition of Sigilon Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"SIG-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sigilon Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Sigilon Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ABA-201","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Abata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Stem Cell-derived Pancreatic Islets","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"Porosome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Porosome Therapeutics Announces Groundbreaking Approach to Advance Diabetes Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"T1D-PT101","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Porosome Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porosome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Porosome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Encellin","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"ENC-201","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Encellin","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Encellin \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Encellin \/ Khosla Ventures"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoping its GLP-1 gene therapy can beat Wegovy, Fractyl plans IPO","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"AAV-based Pancreatic Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ BofA Securities","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ BofA Securities"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva\u00ae GLP-1 Gene Therapy Platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV-Delivered Pancreatic Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"TRx BIOSCIENCES","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arecor and TRX Biosciences Establish Research Collaboration to Develop Oral Glp-1 with Enhanced Bioavailability","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arecor \/ TRx BIOSCIENCES","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ TRx BIOSCIENCES"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"UP421","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1865 million","upfrontCash":"$65.0 million","newsHeadline":"Repertoire\u00ae Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":1.8700000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.8700000000000001,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arecor","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arecor and Medtronic Diabetes Establish Collaboration to Develop a Novel Thermostable Insulin for Implantable Pump Delivery","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Arecor \/ Medtronic Plc","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ Medtronic Plc"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Beta Bionics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Beta Bionics","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Pharmaceuticals \/ Beta Bionics"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Develops iPSCelz\u00ae to Produce Human Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Producing Islet Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laxxon Medical Develops Non-Invasive 3D Printed Oral GLP-1 Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"LXM.2","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laxxon Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Not Applicable"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NephroDI Secures Investment to Develop NDI-5001 for Pediatric Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"NDI-5001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NephroDI Therapeutics \/ Sound Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ Sound Bioventures"},{"orgOrder":0,"company":"Biosplice","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosplice, Novo Nordisk Partner to Develop Drug Candidates for Treatment of Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biosplice \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Biosplice \/ Novo Nordisk"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year